Navigation Links
Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc
Date:5/4/2009

DUBLIN, May 4 /PRNewswire/ -- Circ Pharma Limited ("Circ Pharma") and Elan Corporation plc ("Elan") today announced that they have entered into a Development Agreement to develop a chronotherapeutic formulation of Tramadol for the treatment of moderate to moderately severe pain.

The product incorporates Circ Pharma's proprietary drug delivery technology enabling once daily dosing. Circ's technology provides for minimized delivery to the body during sleeping hours, acceleration of drug absorption immediately prior to the waking hours and the subsequent maintenance of efficacious drug levels for the remainder of the waking hours. Circ has successfully completed Phase I testing on the product.

Currently the worldwide market for pain treatments is worth about US$26 billion and is forecast to grow to about $31 billion by 2011. In the US and Europe the moderate to severe pain market was estimated to be worth about $6.7 billion in 2007. The tramadol market in the US and Europe was worth about $1.1 billion in 2008.

Circ Pharma intends to seek a licensing partner for worldwide commercial distribution of the product.

The agreement with Elan provides that Elan support the continued formulation and manufacturing activities required to seek regulatory approval for this product in the United States and elsewhere. "Elan's extensive experience, know-how and technology for the development and manufacture of scheduled products for the US market will ensure that we can quickly and efficiently complete all the development and clinical activities required for Chrono Tramadol" said Circ Pharma's Chief Technical Officer, Margot Foynes.

About Circ Pharma

Circ Pharma is a specialty pharmaceutical product development company whose mission is to develop differentiated novel formulations of products based on existing drugs that provide incremental patient benefit. Circ Pharma has a strong intellectual property portfolio and technology in the areas of targeted and chronotherapeutic drug delivery and a broad clinical stage pipeline of novel product opportunities in a number of indications including cardiovascular and pain indications. http://www.circpharma.com

    Further Information:

    Media Contact
    Mr. Ray Gordon, Gordon MRM
    Telephone: +353-1-6650450
    E-mail: ray@gordonmrm.ie



'/>"/>
SOURCE Circ Pharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
2. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
3. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
4. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
5. Idenix Pharmaceuticals Reports First Quarter Financial Results
6. Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. Vanda Pharmaceuticals Reports First Quarter 2009 Results
11. Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Bethesda, MD (PRWEB) , ... January 18, 2017 ... ... for the National Institutes of Health (NIH) to update its Data Sharing Policy. ... a “scoreable” element of grant applications subject to the existing policy. AMIA recommended ...
(Date:1/19/2017)... ... 2017 , ... FireflySci Inc. is a go-getter type of company that continues ... to two main factors. The first is the amazing customer service that the ... products all around the world. , 2016 was a tremendous sales year for FFS ...
(Date:1/19/2017)... 18, 2017 The global biotechnology services ... billion by 2025, according to a new report ... been adaptive of the function of outsourcing certain ... Among the services outsourced, clinical trial management and ... & Johnson was the first pharmaceutical company to ...
(Date:1/19/2017)... Jan. 18, 2017 Acupath Laboratories, Inc., a ... formation of an Executive Committee that will guide the ... John Cucci , a 15-year veteran of ... of Business Development to Chief Sales Officer .  ... served in senior sales leadership roles at several leading ...
Breaking Biology Technology:
(Date:12/22/2016)... 22, 2016 SuperCom (NASDAQ:   ... for the e-Government, Public Safety, HealthCare, and Finance sectors announced today ... been selected to implement and deploy a community-based supportive services program ... California , further expanding its presence in the state. ... This new program, which ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   ... data sensor technology, and STMicroelectronics (NYSE: ... spectrum of electronics applications, announced today the launch ... kit for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, ...
(Date:12/16/2016)... 16, 2016   IdentyTechSolutions America LLC , ... and solutions and a cutting-edge manufacturer of software ... is offering seamless, integrated solutions that comprise IDT ... The solutions provide IdentyTech,s customers with combined physical ... from crime and theft. "We are ...
Breaking Biology News(10 mins):